This study was presented as a poster (Guided Tour 2) at the Twelfth International Congress of Parkinson's Disease and Movement Disorders, Chicago, 2008 (poster #600).
Article first published online: 15 APR 2009
Copyright © 2009 Movement Disorder Society
Volume 24, Issue 8, pages 1217–1221, 15 June 2009
How to Cite
Leroi, I., Overshott, R., Byrne, E. J., Daniel, E. and Burns, A. (2009), Randomized controlled trial of memantine in dementia associated with Parkinson's disease. Mov. Disord., 24: 1217–1221. doi: 10.1002/mds.22495
The authors take full responsibility for the content of the manuscript. This study was sponsored by an unrestricted grant from Lundbeck, Inc., which means that the conceptualization, design, undertaking, analysis, and manuscript preparation were undertaken entirely by the authors. We have given Lundbeck, Inc., full access to the manuscript; however, they have not seen the raw data. None of the authors is federal employees in the USA or United Kingdom and there is no previous copyright on the manuscript.
Potential conflict of interest: Drs. Leroi and Byrne and Prof. Burns have received honoraria for presentations from H. Lundbeck A/S. Dr. Leroi has received an unrestricted grant from H. Lundbeck A/S for this study (see Acknowledgments).
- Issue published online: 18 JUN 2009
- Article first published online: 15 APR 2009
- Manuscript Accepted: 15 JAN 2009
- Manuscript Revised: 12 JAN 2009
- Manuscript Received: 11 OCT 2008
- H. Lundbeck A/S
- Parkinson's disease dementia;
- clinical trial;
- cognitive impairment
The objective of this study is to investigate the safety and tolerability of memantine, a glutamatergic modulator, in patients suffering from dementia associated with Parkinson's disease (PDD), an increasingly common complication of PD. This was a 22-week trial of 25 participants with a DSM-IV diagnosis of PDD who were randomized to either placebo or 20 mg/day of memantine. Memantine was well tolerated by participants at 20 mg/day dosing. No participant was withdrawn due to memantine-related adverse events. Six weeks after drug withdrawal, a significantly greater proportion (P = 0.04) of memantine-treated participants deteriorated globally compared with those treated with placebo. These findings suggest that continued treatment with memantine may be needed to maintain global level of functioning over time. Based on the findings of this pilot study, memantine is safe and very well-tolerated in PDD. © 2009 Movement Disorder Society